These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

808 related articles for article (PubMed ID: 20186853)

  • 21. Hypothetical Preclinical Alzheimer Disease Groups and Longitudinal Cognitive Change.
    Soldan A; Pettigrew C; Cai Q; Wang MC; Moghekar AR; O'Brien RJ; Selnes OA; Albert MS;
    JAMA Neurol; 2016 Jun; 73(6):698-705. PubMed ID: 27064267
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mood Changes in Cognitively Normal Older Adults are Linked to Alzheimer Disease Biomarker Levels.
    Babulal GM; Ghoshal N; Head D; Vernon EK; Holtzman DM; Benzinger TLS; Fagan AM; Morris JC; Roe CM
    Am J Geriatr Psychiatry; 2016 Nov; 24(11):1095-1104. PubMed ID: 27426238
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serial MRI and CSF biomarkers in normal aging, MCI, and AD.
    Vemuri P; Wiste HJ; Weigand SD; Knopman DS; Trojanowski JQ; Shaw LM; Bernstein MA; Aisen PS; Weiner M; Petersen RC; Jack CR;
    Neurology; 2010 Jul; 75(2):143-51. PubMed ID: 20625167
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interactions between apolipoprotein E, sex, and amyloid-beta on cerebrospinal fluid p-tau levels in the European prevention of Alzheimer's dementia longitudinal cohort study (EPAD LCS).
    Saunders TS; Jenkins N; Blennow K; Ritchie C; Muniz-Terrera G
    EBioMedicine; 2022 Sep; 83():104241. PubMed ID: 36041266
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Imaging and cerebrospinal fluid biomarkers in early preclinical alzheimer disease.
    Vlassenko AG; McCue L; Jasielec MS; Su Y; Gordon BA; Xiong C; Holtzman DM; Benzinger TL; Morris JC; Fagan AM
    Ann Neurol; 2016 Sep; 80(3):379-87. PubMed ID: 27398953
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type.
    Snider BJ; Fagan AM; Roe C; Shah AR; Grant EA; Xiong C; Morris JC; Holtzman DM
    Arch Neurol; 2009 May; 66(5):638-45. PubMed ID: 19433664
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype.
    Galasko D; Chang L; Motter R; Clark CM; Kaye J; Knopman D; Thomas R; Kholodenko D; Schenk D; Lieberburg I; Miller B; Green R; Basherad R; Kertiles L; Boss MA; Seubert P
    Arch Neurol; 1998 Jul; 55(7):937-45. PubMed ID: 9678311
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CSF Apo-E levels associate with cognitive decline and MRI changes.
    Toledo JB; Da X; Weiner MW; Wolk DA; Xie SX; Arnold SE; Davatzikos C; Shaw LM; Trojanowski JQ;
    Acta Neuropathol; 2014 May; 127(5):621-32. PubMed ID: 24385135
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Toward a multifactorial model of Alzheimer disease.
    Storandt M; Head D; Fagan AM; Holtzman DM; Morris JC
    Neurobiol Aging; 2012 Oct; 33(10):2262-71. PubMed ID: 22261556
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.
    Sunderland T; Mirza N; Putnam KT; Linker G; Bhupali D; Durham R; Soares H; Kimmel L; Friedman D; Bergeson J; Csako G; Levy JA; Bartko JJ; Cohen RM
    Biol Psychiatry; 2004 Nov; 56(9):670-6. PubMed ID: 15522251
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of Amyloid Pathology With Myelin Alteration in Preclinical Alzheimer Disease.
    Dean DC; Hurley SA; Kecskemeti SR; O'Grady JP; Canda C; Davenport-Sis NJ; Carlsson CM; Zetterberg H; Blennow K; Asthana S; Sager MA; Johnson SC; Alexander AL; Bendlin BB
    JAMA Neurol; 2017 Jan; 74(1):41-49. PubMed ID: 27842175
    [TBL] [Abstract][Full Text] [Related]  

  • 32. APOE4 allele disrupts resting state fMRI connectivity in the absence of amyloid plaques or decreased CSF Aβ42.
    Sheline YI; Morris JC; Snyder AZ; Price JL; Yan Z; D'Angelo G; Liu C; Dixit S; Benzinger T; Fagan A; Goate A; Mintun MA
    J Neurosci; 2010 Dec; 30(50):17035-40. PubMed ID: 21159973
    [TBL] [Abstract][Full Text] [Related]  

  • 33. APOE modulates the effect of estrogen therapy on Aβ accumulation EFAD-Tg mice.
    Kunzler J; Youmans KL; Yu C; Ladu MJ; Tai LM
    Neurosci Lett; 2014 Feb; 560():131-6. PubMed ID: 24368217
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Plasma Aβ42/40 Ratio Detects Early Stages of Alzheimer's Disease and Correlates with CSF and Neuroimaging Biomarkers in the AB255 Study.
    Pérez-Grijalba V; Romero J; Pesini P; Sarasa L; Monleón I; San-José I; Arbizu J; Martínez-Lage P; Munuera J; Ruiz A; Tárraga L; Boada M; Sarasa M
    J Prev Alzheimers Dis; 2019; 6(1):34-41. PubMed ID: 30569084
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Circadian Rest-Activity Pattern Changes in Aging and Preclinical Alzheimer Disease.
    Musiek ES; Bhimasani M; Zangrilli MA; Morris JC; Holtzman DM; Ju YS
    JAMA Neurol; 2018 May; 75(5):582-590. PubMed ID: 29379963
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults.
    Fagan AM; Roe CM; Xiong C; Mintun MA; Morris JC; Holtzman DM
    Arch Neurol; 2007 Mar; 64(3):343-9. PubMed ID: 17210801
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preclinical effects of APOE ε4 on cerebrospinal fluid Aβ42 concentrations.
    Lautner R; Insel PS; Skillbäck T; Olsson B; Landén M; Frisoni GB; Herukka SK; Hampel H; Wallin A; Minthon L; Hansson O; Blennow K; Mattsson N; Zetterberg H
    Alzheimers Res Ther; 2017 Oct; 9(1):87. PubMed ID: 29061195
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease.
    Fagan AM; Mintun MA; Shah AR; Aldea P; Roe CM; Mach RH; Marcus D; Morris JC; Holtzman DM
    EMBO Mol Med; 2009 Nov; 1(8-9):371-80. PubMed ID: 20049742
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hippocampal atrophy rates and CSF biomarkers in elderly APOE2 normal subjects.
    Chiang GC; Insel PS; Tosun D; Schuff N; Truran-Sacrey D; Raptentsetsang ST; Jack CR; Aisen PS; Petersen RC; Weiner MW;
    Neurology; 2010 Nov; 75(22):1976-81. PubMed ID: 20980669
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oligomeric forms of amyloid-β protein in plasma as a potential blood-based biomarker for Alzheimer's disease.
    Wang MJ; Yi S; Han JY; Park SY; Jang JW; Chun IK; Kim SE; Lee BS; Kim GJ; Yu JS; Lim K; Kang SM; Park YH; Youn YC; An SSA; Kim S
    Alzheimers Res Ther; 2017 Dec; 9(1):98. PubMed ID: 29246249
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.